{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:27Z","timestamp":1790351427140,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00277-024-05662-7","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T04:01:32Z","timestamp":1712116892000},"page":"4045-4055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study"],"prefix":"10.1007","volume":"103","author":[{"given":"Luc\u00eda","family":"P\u00e9rez-Lamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"de Paz Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M\u00aa Ayala","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe Casado","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Ram\u00edrez","family":"Payer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca Ferrer","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal P\u00e9rez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Xicoy","family":"Cirici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"5662_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP et al (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30:1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"5662_CR2","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM et al (2016) Final 5-Year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic myeloid leukemia patients trial. J Clin Oncol 34:2333\u20132340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"5662_CR3","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Br\u00fcmmendorf","year":"2022","unstructured":"Br\u00fcmmendorf TH, Cortes JE, Milojkovic D et al (2022) Bosutinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia 36:1825\u20131833. https:\/\/doi.org\/10.1038\/s41375-022-01589-y","journal-title":"Leukemia"},{"key":"5662_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"5662_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","volume":"77","author":"L Campiotti","year":"2017","unstructured":"Campiotti L, Suter MB, Guasti L et al (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 77:48\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.028","journal-title":"Eur J Cancer"},{"key":"5662_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97:1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol"},{"key":"5662_CR7","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1080\/10428194.2022.2090549","volume":"63","author":"Z Xu","year":"2022","unstructured":"Xu Z, Yin J, Sun Q et al (2022) The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation. Leuk Lymphoma 63:2616\u20132626. https:\/\/doi.org\/10.1080\/10428194.2022.2090549","journal-title":"Leuk Lymphoma"},{"key":"5662_CR8","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.3390\/cancers13235904","volume":"13","author":"Y Fujioka","year":"2021","unstructured":"Fujioka Y, Sugiyama D, Matsumura I et al (2021) Regulatory T cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia. Cancers (Basel) 13:5904. https:\/\/doi.org\/10.3390\/cancers13235904","journal-title":"Cancers (Basel)"},{"key":"5662_CR9","doi-asserted-by":"crossref","unstructured":"Mu H, Zhu X, Jia H et al (2021) Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and Immune Modulation. Front Oncol 11","DOI":"10.3389\/fonc.2021.643382"},{"key":"5662_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1182\/hematology.2021000238","volume":"2021","author":"A Hochhaus","year":"2021","unstructured":"Hochhaus A, Ernst T (2021) TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission? Hematology 2021:106\u2013112. https:\/\/doi.org\/10.1182\/hematology.2021000238","journal-title":"Hematology"},{"key":"5662_CR11","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","volume":"35","author":"F Guilhot","year":"2021","unstructured":"Guilhot F, Rigal-Huguet F, Guilhot J et al (2021) Long-term outcome of imatinib 400\u00a0mg compared to imatinib 600\u00a0mg or imatinib 400\u00a0mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial. Leukemia 35:2332\u20132345. https:\/\/doi.org\/10.1038\/s41375-020-01117-w","journal-title":"Leukemia"},{"key":"5662_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bjh.18486","volume":"200","author":"L Roy","year":"2023","unstructured":"Roy L, Chomel J, Guilhot J et al (2023) Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: results of a multicenter phase 2 study (DASA-PegIFN study). Br J Haematol 200:175\u2013186. https:\/\/doi.org\/10.1111\/bjh.18486","journal-title":"Br J Haematol"},{"key":"5662_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/bjh.18984","volume":"202","author":"YD Irani","year":"2023","unstructured":"Irani YD, Hughes A, Kok CH et al (2023) Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. Br J Haematol 202:1127\u20131136. https:\/\/doi.org\/10.1111\/bjh.18984","journal-title":"Br J Haematol"},{"key":"5662_CR14","doi-asserted-by":"publisher","unstructured":"Zhong FM, Yao FY, Yang YL et al (2023) Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia. Cancer Cell Int 23. https:\/\/doi.org\/10.1186\/s12935-023-02905-x","DOI":"10.1186\/s12935-023-02905-x"},{"key":"5662_CR15","doi-asserted-by":"publisher","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E et al (2013) Increased level of myeloid-derived suppressor cells, Programmed Death Receptor Ligand 1\/Programmed death receptor 1, and Soluble CD25 in Sokal High Risk Chronic myeloid leukemia. PLoS ONE 8. https:\/\/doi.org\/10.1371\/journal.pone.0055818","DOI":"10.1371\/journal.pone.0055818"},{"key":"5662_CR16","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1007\/s00262-020-02617-5","volume":"69","author":"MY Lee","year":"2020","unstructured":"Lee MY, Park CJ, Cho YU et al (2020) Differences in PD-1 expression on CD8\u2009+\u2009T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication. Cancer Immunol Immunother 69:2223\u20132232. https:\/\/doi.org\/10.1007\/s00262-020-02617-5","journal-title":"Cancer Immunol Immunother"},{"key":"5662_CR17","doi-asserted-by":"publisher","unstructured":"Hughes A, Clarson J, Tang C et al (2017) Regular article MYELOID NEOPLASIA CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. https:\/\/doi.org\/10.1182\/blood-2016","DOI":"10.1182\/blood-2016"},{"key":"5662_CR18","doi-asserted-by":"crossref","unstructured":"Jimbu L, Mesaros O, Popescu C et al (2021) Is there a place for PD-1-PD-L blockade in acute myeloid leukemia? Pharmaceuticals 14","DOI":"10.3390\/ph14040288"},{"key":"5662_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092592","volume":"12","author":"S De Almeida","year":"2020","unstructured":"De Almeida S, Regimbeau M, Jego G et al (2020) Heat shock proteins and pd-1\/pd-l1 as potential therapeutic targets in myeloproliferative neoplasms. Cancers (Basel) 12:1\u201321","journal-title":"Cancers (Basel)"},{"key":"5662_CR20","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V et al (2016) Programmed Death-1 Blockade with Pembrolizumab in patients with classical Hodgkin Lymphoma after Brentuximab Vedotin Failure. J Clin Oncol 34:3733\u20133739. https:\/\/doi.org\/10.1200\/JCO.2016.67.3467","journal-title":"J Clin Oncol"},{"key":"5662_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"5662_CR22","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1080\/10428194.2021.1889536","volume":"62","author":"J Mart\u00ednez-L\u00f3pez","year":"2021","unstructured":"Mart\u00ednez-L\u00f3pez J, Mustjoki S, Porkka K et al (2021) The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. Leuk Lymphoma 62:2040\u20132043. https:\/\/doi.org\/10.1080\/10428194.2021.1889536","journal-title":"Leuk Lymphoma"},{"key":"5662_CR23","unstructured":"Pembrolizumab, Dasatinib (2023) Oct, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease (NCT03516279). https:\/\/clinicaltrials.gov\/study\/NCT03516279. Accessed 1"},{"key":"5662_CR24","unstructured":"Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW). NCT02767063. https:\/\/clinicaltrials.gov\/study\/NCT02767063?cond=chronic%20myeloid%20leukemia&intr=Avelumab&rank=1. Accessed 29 Jan 2024"},{"key":"5662_CR25","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","journal-title":"Lancet"},{"key":"5662_CR26","unstructured":"Tecentriq technical data sheet. Summary of Product Characteristics"},{"key":"5662_CR27","unstructured":"Bosulif technical data sheet (2023) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bosulif-epar-product-information_en.pdf. Accessed 1"},{"key":"5662_CR28","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"5662_CR29","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","volume":"126","author":"H Li","year":"2022","unstructured":"Li H, van der Merwe PA, Sivakumar S (2022) Biomarkers of response to PD-1 pathway blockade. Br J Cancer 126:1663\u20131675","journal-title":"Br J Cancer"},{"key":"5662_CR30","doi-asserted-by":"publisher","first-page":"e2120165","DOI":"10.1001\/jamanetworkopen.2021.20165","volume":"4","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wang X, Wang Z et al (2021) Comparison of Hepatotoxicity Associated with New BCR-ABL tyrosine kinase inhibitors vs Imatinib among patients with chronic myeloid leukemia. JAMA Netw Open 4:e2120165. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20165","journal-title":"JAMA Netw Open"},{"key":"5662_CR31","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F et al (2020) First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv 4:2723\u20132735","journal-title":"Blood Adv"},{"key":"5662_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/17425255.2015.983075","volume":"11","author":"YL Teo","year":"2015","unstructured":"Teo YL, Ho HK, Chan A (2015) Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol 11:231\u2013242. https:\/\/doi.org\/10.1517\/17425255.2015.983075","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5662_CR33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bulcan.2017.11.015","volume":"105","author":"D B\u00e9chade","year":"2018","unstructured":"B\u00e9chade D, Chakiba C, Desjardin M et al (2018) Toxicit\u00e9 h\u00e9patique des inhibiteurs des tyrosines kinases: m\u00e9canismes en cause et cons\u00e9quences pratiques. Bull Cancer 105:290\u2013298. https:\/\/doi.org\/10.1016\/j.bulcan.2017.11.015","journal-title":"Bull Cancer"},{"key":"5662_CR34","doi-asserted-by":"crossref","unstructured":"De Martin E, Michot JM, Rosmorduc O et al (2020) Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep 2","DOI":"10.1016\/j.jhepr.2020.100170"},{"key":"5662_CR35","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181\u20131190. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.033","journal-title":"J Hepatol"},{"key":"5662_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000509081","volume":"106","author":"D K\u00f6nig","year":"2021","unstructured":"K\u00f6nig D, L\u00e4ubli H (2021) Mechanisms of Immune-Related complications in Cancer patients treated with Immune Checkpoint inhibitors. Pharmacology 106:123\u2013136","journal-title":"Pharmacology"},{"key":"5662_CR37","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","volume":"11","author":"L Shojaie","year":"2021","unstructured":"Shojaie L, Ali M, Iorga A, Dara L (2021) Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B 11:3727\u20133739","journal-title":"Acta Pharm Sin B"},{"key":"5662_CR38","doi-asserted-by":"publisher","unstructured":"Endo Y, Winarski KL, Sajib MS et al (2023) Atezolizumab induces necroptosis and contributes to Hepatotoxicity of Human hepatocytes. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241411694","DOI":"10.3390\/ijms241411694"},{"key":"5662_CR39","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM et al (2012) Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486\u20133492. https:\/\/doi.org\/10.1200\/JCO.2011.38.7522","journal-title":"J Clin Oncol"},{"key":"5662_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384:829\u2013841. https:\/\/doi.org\/10.1056\/NEJMoa2026982","journal-title":"N Engl J Med"},{"key":"5662_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P et al (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402:185\u2013195. https:\/\/doi.org\/10.1016\/S0140-6736(23)00922-4","journal-title":"Lancet"},{"key":"5662_CR42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y et al (2021) Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384:1289\u20131300. https:\/\/doi.org\/10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"5662_CR43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/cancers15030947","volume":"15","author":"K Iinuma","year":"2023","unstructured":"Iinuma K, Yamada T, Kameyama K et al (2023) The efficacy and safety of Immune checkpoint inhibitor and tyrosine kinase inhibitor combination therapy for Advanced or metastatic renal cell carcinoma: a Multicenter Retrospective Real-World Cohort Study. Cancers (Basel) 15:947. https:\/\/doi.org\/10.3390\/cancers15030947","journal-title":"Cancers (Basel)"},{"key":"5662_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A et al (2022) Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 386:437\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa2108330","journal-title":"N Engl J Med"},{"key":"5662_CR45","unstructured":"A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patient (NCT05078931). https:\/\/clinicaltrials.gov\/study\/NCT05078931. Accessed 1 Oct 2023"},{"key":"5662_CR46","doi-asserted-by":"publisher","first-page":"175883401774501","DOI":"10.1177\/1758834017745012","volume":"10","author":"I Moya-Horno","year":"2018","unstructured":"Moya-Horno I, Viteri S, Karachaliou N, Rosell R (2018) Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol 10:175883401774501. https:\/\/doi.org\/10.1177\/1758834017745012","journal-title":"Ther Adv Med Oncol"},{"key":"5662_CR47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles T, Plimack ER, Souli\u00e8res D et al (2020) Pembrolizumab plus Axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21:1563\u20131573. https:\/\/doi.org\/10.1016\/S1470-2045(20)30436-8","journal-title":"Lancet Oncol"},{"key":"5662_CR48","unstructured":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (TIDE-A) (NCT04698213). https:\/\/clinicaltrials.gov\/study\/NCT04698213. Accessed 2 Oct 2023"},{"key":"5662_CR49","unstructured":"Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic\/\u200bAdvanced Pancreatic or Colorectal Cancers (MEDIPLEX) (NCT02777710). https:\/\/clinicaltrials.gov\/study\/NCT02777710. Accessed 2 Oct 2023"},{"key":"5662_CR50","unstructured":"Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma (GliAvAx) (NCT03291314). https:\/\/clinicaltrials.gov\/study\/NCT03291314. Accessed 2 Oct 2023"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05662-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05662-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05662-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:03:15Z","timestamp":1729933395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05662-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5662"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05662-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"2 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The design, submission and monitoring of this study was performed in collaboration with the Contract Research Organization Fundaci\u00f3n Te\u00f3filo Hernando, in accordance with their standard operating procedures, which comply with the ethical principles of Good Clinical Practice, and in accordance with the current Declaration of Helsinki (Fortaleza, Brazil, October 2013). The study was approved by the independent ethics committee of each participating center and by the Spanish Agency of Medicines and Health Products (AEMPS). All patients gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Aproval"}},{"value":"L. P\u00e9rez Lamas: Novartis; travel grants. Incyte; travel grants. B. Xicoy: Novartis, Incyte; travel grants, research funding, advisory board; BMS and Pfizer: travel grants, advisory board. R. Ayala: Advisory board member for BMS, Novartis and Incyte. Received speaker honoraria from Astellas, Novartis and BMS.F. Ferrer Mar\u00edn: Advisory board member for BMS and Novartis. Received speaker honoraria from Novartis and BMS. Received grants from CTI and Incyte. V. Garcia-Gutierrez: Novartis; BMS; Incyte; Pfizer; travel grants, research funding, advisory board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}